官方服务：
资源简介：
NGS of patients progressed to ALK inhibitors
应用场景：
创建时间：
2023-05-23
相关数据集
Design, Synthesis, and Biological Evaluation of Pyrimido[4,5‑ d ]pyrimidine-2,4(1 H ,3 H )‑diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation
First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clinical efficacy for nonsmall cell lung cancer (NSCLC) patients with EGFR
NIAID Data Ecosystem60
Nucleus-Translocated GCLM Promotes Chemoresistance in Colorectal Cancer through a Moonlighting Function
Emerging evidence indicates that metabolic enzymes perform moonlighting functions during tumor progression, including the modulation of chemoresistance. However, the underlying mechanisms of these fun
NIAID Data Ecosystem50
Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens
Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types
NIAID Data Ecosystem40
ChIP-seq profiles of primary, metastatic, drug-resistant and drug-holiday cells
We employed ChIP-seq to detect poised and active chromatin regions in cisplatin sensitive and resistant head neck squamous cell carcinoma patient derived primary and lymph node cell lines. Examination
NIAID Data Ecosystem60
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are requir
NIAID Data Ecosystem50
